This highlights the molecular diversity of EGFR-mutant NSCLC and emphasizes the increasing recognition of the clinical importance of uncommon EGFR mutations, many of which show variable sensitivity to tyrosine kinase inhibitors (TKIs) [17]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.